Severine Alran

Summary

Affiliation: Institut Curie
Country: France

Publications

  1. ncbi Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy
    Severine Alran
    Department of Surgical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Ann Surg Oncol 14:2195-201. 2007
  2. ncbi The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 6:e20297. 2011
  3. ncbi Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer
    Christophe Le Tourneau
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Am J Clin Oncol 35:242-6. 2012
  4. ncbi High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Breast 21:380-3. 2012
  5. ncbi Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma
    Anne Vincent-Salomon
    Department of Pathology, Institut Curie, 75005 Paris Cedex, France
    Eur J Cancer 45:1979-86. 2009
  6. ncbi A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer
    Jean Philippe Meyniel
    Department of Translational Research, Institut Curie, 26 Rue d Ulm, 75248 Paris, Cedex 05, France
    BMC Cancer 10:222. 2010
  7. ncbi Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome
    Pascale This
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248, Paris Cedex 05, France
    Fam Cancer 11:473-82. 2012
  8. ncbi Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
    Anne Marszalek
    Department of Surgery, Institut Curie, 25 rue d Ulm, 75005 Paris, France
    Int J Surg Oncol 2010:214919. 2010
  9. ncbi Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients
    Maura Campitelli
    Department of Radiation Oncology, Institut Curie, Hospital, Paris, France
    PLoS ONE 7:e43393. 2012
  10. ncbi Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype
    Patricia De Cremoux
    Department of Tumour Biology, Institut Curie, Paris, France
    Int J Cancer 124:778-82. 2009

Collaborators

Detail Information

Publications10

  1. ncbi Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy
    Severine Alran
    Department of Surgical Oncology, Institut Curie, 26 Rue d Ulm, 75005 Paris, France
    Ann Surg Oncol 14:2195-201. 2007
    ..The purpose of this study was to test the accuracy of the nomogram on patients with macrometastatic and micrometastatic SLN-positive biopsy findings...
  2. ncbi The molecular subtype classification is a determinant of sentinel node positivity in early breast carcinoma
    Fabien Reyal
    Department of Surgery, Institut Curie, Paris, France
    PLoS ONE 6:e20297. 2011
    ..The aim of our work was to decipher the interaction between this classification and the probability of a positive sentinel node biopsy...
  3. ncbi Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer
    Christophe Le Tourneau
    Department of Medical Oncology, Institut Curie, 26 Rue d Ulm, Paris Cedex 05, France
    Am J Clin Oncol 35:242-6. 2012
    ....
  4. ncbi High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients
    Anne Vincent-Salomon
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248 Paris Cedex 05, France
    Breast 21:380-3. 2012
    ..Our aim was to evaluate the risk of relapse for lobular carcinoma in situ (LCIS) patients, diagnosed on mammography performed for microcalcifications and according to proliferation assessed by Ki67 staining...
  5. ncbi Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma
    Anne Vincent-Salomon
    Department of Pathology, Institut Curie, 75005 Paris Cedex, France
    Eur J Cancer 45:1979-86. 2009
    ....
  6. ncbi A genomic and transcriptomic approach for a differential diagnosis between primary and secondary ovarian carcinomas in patients with a previous history of breast cancer
    Jean Philippe Meyniel
    Department of Translational Research, Institut Curie, 26 Rue d Ulm, 75248 Paris, Cedex 05, France
    BMC Cancer 10:222. 2010
    ..The purpose of the present work was to develop genomic and transcriptomic tools to further refine the pathological diagnosis of ovarian tumors after a previous history of breast cancer...
  7. ncbi Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome
    Pascale This
    Department of Tumor Biology, Institut Curie, 26 Rue d Ulm, 75248, Paris Cedex 05, France
    Fam Cancer 11:473-82. 2012
    ..However, good compliance with prophylactic salpingo-oophorectomy was observed. This study confirms the high breast cancer risk in these women...
  8. ncbi Outcome in Advanced Ovarian Cancer following an Appropriate and Comprehensive Effort at Upfront Cytoreduction: A Twenty-Year Experience in a Single Cancer Institute
    Anne Marszalek
    Department of Surgery, Institut Curie, 25 rue d Ulm, 75005 Paris, France
    Int J Surg Oncol 2010:214919. 2010
    ..The impact of neoadjuvant chemotherapy to improve resectability while lowering the morbidity of the surgical procedure is discussed...
  9. ncbi Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients
    Maura Campitelli
    Department of Radiation Oncology, Institut Curie, Hospital, Paris, France
    PLoS ONE 7:e43393. 2012
    ..To determine whether the sequence of the cell-viral junction could be used in clinical practice as a specific marker of ctDNA, we analyzed a series of cervical cancer patient serums...
  10. ncbi Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype
    Patricia De Cremoux
    Department of Tumour Biology, Institut Curie, Paris, France
    Int J Cancer 124:778-82. 2009
    ..One third of invasive carcinoma were not associated with HPV 16/18, indicating that the screening for cervical neoplasia should be maintained after prophylactic vaccination against these HPV genotypes...